Free Trial
NASDAQ:RLYB

Rallybio Q3 2024 Earnings Report

Rallybio logo
$0.43 -0.02 (-5.43%)
Closing price 04:00 PM Eastern
Extended Trading
$0.43 +0.00 (+0.23%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rallybio EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Rallybio Revenue Results

Actual Revenue
$0.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Rallybio Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Rallybio's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Rallybio Earnings Headlines

Rallybio (NASDAQ:RLYB) Shares Up 4.4% - Should You Buy?
Evercore ISI Remains a Hold on Rallybio (RLYB)
Missed the Run So Far? This Is Your Second Chance
According to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.
See More Rallybio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rallybio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rallybio and other key companies, straight to your email.

About Rallybio

Rallybio (NASDAQ:RLYB) is a clinical-stage biotechnology company dedicated to developing transformative therapies for patients with rare diseases. Since its founding in 2020, the company has built a diversified pipeline of therapeutic candidates that leverage protein replacement, antibody-based modalities, and novel small molecules. Rallybio focuses on areas of high unmet medical need, including complement-mediated disorders, lysosomal storage diseases and genetic cardiometabolic conditions.

Rallybio’s lead programs encompass multiple stages of clinical development. Among these, a complement inhibitor targeting paroxysmal nocturnal hemoglobinuria and related indications is in late-stage study, while enzyme replacement and substrate reduction approaches are advancing for select mucopolysaccharidoses. The company also pursues earlier-stage candidates for alpha-1 antitrypsin deficiency and other genetic disorders, drawing on partnerships with academic institutions and technology platforms to accelerate discovery and development.

Headquartered in Waltham, Massachusetts, Rallybio conducts clinical trials across the United States and Europe, collaborating with a global network of investigative sites. The company maintains strategic alliances for manufacturing and process development to support its pipeline, and leverages real-world evidence initiatives and patient advocacy groups to inform trial design and ensure patient-centric approaches.

Rallybio’s leadership team combines deep industry experience and scientific expertise. Chief Executive Officer Thomas W. Lynch brings over two decades of biopharma leadership, including senior roles in research and development. The broader executive team and board of directors feature seasoned professionals with backgrounds in commercial strategy, regulatory affairs and rare disease drug development, all united in Rallybio’s mission to bring novel therapies to patients with limited or no treatment options.

View Rallybio Profile

More Earnings Resources from MarketBeat